Abstract

ObjectiveWe previously reported that patients with cholesteryl ester transfer protein (CETP) deficiency (CETP-D) have a higher prevalence of atherosclerotic cardiovascular disease, in spite of increased HDL-C levels. However, characterization of HDL in CETP-D has not been well described. Therefore, we examined HDL particle number (PN) rather than HDL-C level.Approach and resultsNine patients with CETP-D and 9 normolipidemic subjects were enrolled. We performed gel permeation high-performance liquid chromatography (GP-HPLC) analysis, determined the cholesterol and triglyceride composition of all lipoprotein subclasses, and calculated the PN of each subclass, which consisted of 3 VLDL (large, medium, and small), 4 LDL (large, medium, small, and very small), and 5 HDL (very large, large, medium, small, and very small) subclasses. The PNs of large and medium LDL were significantly lower in CETP-D than that in healthy subjects (0.66- and 0.63-fold decrease, respectively; p<0.001), whereas the PN of very small LDL, which is known to be atherogenic, was significantly higher (1.36-fold increase, p = 0.016). The PNs of very large and large HDL in CETP-D were markedly higher than that in healthy subjects (19.9- and 4.5-fold increase, respectively; p<0.001), whereas the PNs of small and very small HDL, which have more potent anti-atherogenic functions, were significantly lower (0.76- and 0.61-fold decrease, respectively; p<0.001).ConclusionWe have assessed the PNs of detailed subclasses of patients with CETP-D for the first time. The PN of larger HDL was markedly increased, that of smaller HDL was decreased, and that of very small LDL was increased, suggesting that CETP-D has pro-atherogenic lipoprotein properties.

Highlights

  • Epidemiological studies have shown that high LDL-cholesterol (LDL-C) and low HDL-cholesterol (HDL-C) levels are positively and independently correlated with cardiovascular disease (CVD) events[1]

  • We have assessed the particle number (PN) of detailed subclasses of patients with cholesteryl ester transfer protein (CETP)-D for the first time

  • We previously reported that patients with hyperalphalipoproteinemia (HALP) caused by CETP deficiency (CETP-D), who showed similar lipid profiles to CETP inhibitor-treated patients, were not protected against CVD[9]

Read more

Summary

Introduction

Epidemiological studies have shown that high LDL-cholesterol (LDL-C) and low HDL-cholesterol (HDL-C) levels are positively and independently correlated with cardiovascular disease (CVD) events[1]. Drugs that increase HDL-C levels, such as niacin[4] and most cholesteryl ester transfer protein (CETP) inhibitors, have been unable to reduce CVD events. Studies of the CETP inhibitors torcetrapib[5], dalcetrapib[6], and evacetrapib[7] were terminated because of increased mortality or no significant effects on major CVD events, these drugs increased HDL-C or even decreased LDL-C levels. We previously reported that patients with hyperalphalipoproteinemia (HALP) caused by CETP deficiency (CETP-D), who showed similar lipid profiles to CETP inhibitor-treated patients, were not protected against CVD[9]. We hypothesized that inhibition or deficiency of CETP might affect the structural alterations of lipoproteins, including lipoprotein particle distribution or lipoprotein particle numbers (PNs)

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.